2030 here we come

The pharma and lifesciences ecosystem was already facing significant opportunities and disruption from technology advances, pricing pressure, digital and new entrants. In a Covid-19 world and with Brexit uncertainty the level of disruption has only been amplified. This panel will explore the disruptive themes and key success factors for companies to navigate our changing environment.


JO PISANI | Strategic Advisor, Non Executive Director and Charity Trustee


JOHN DAWSON | Chief Executive Officer | Oxford Biomedica
RICHARD TORBETT | Chief Executive Officer | ABPI
BRIAN HENRY | Vice President, Global Head of Drug Product Design | Pfizer Worldwide Research and Development
GLENN CROCKER | Head of Life Sciences, JLL & Chairman, BioCity Group | JLL & BioCity Group
NICOLE MATHER | Executive Partner, Life Sciences Lead | IBM Services